Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options
